Summary During eukaryotic evolution, ribosomes have considerably increased in size forming a surface exposed ribosomal RNA (rRNA) shell of unknown function, which may create an interface for yet uncharacterized interacting proteins. To investigate such protein interactions, we establish a ribosome affinity purification method that unexpectedly identified hundreds of ribosome associated proteins (RAPs) from categories including metabolism, cell cycle, as well as RNA and protein modifying enzymes that functionally diversify mammalian ribosomes. By further characterizing RAPs, we discover the presence of ufmylation, a metazoan-specific posttranslational modification, on ribosomes and define its direct substrates. Moreover, we show that the metabolic enzyme, pyruvate kinase muscle (PKM), interacts with sub-pools of endoplasmic reticulum (ER)-associated ribosomes, exerting a non-canonical function as an RNA binding protein in the translation of ER-destined mRNAs. Therefore, RAPs interconnect one of life’s most ancient molecular machines with diverse cellular processes, providing an additional layer of regulatory potential to protein expression.

Chromosomal translocations in hematologic and mesenchymal tumors form overwhelmingly by nonhomologous end-joining (NHEJ). Canonical NHEJ, essential for the repair of radiation-induced and some programmed double-strand breaks (DSBs), requires the Xrcc4/ligase IV complex. For other DSBs, the requirement for Xrcc4/ligase IV is less stringent, suggesting the existence of alternative end-joining (alt-NHEJ) pathways. To understand the contribution of the canonical and alt-NHEJ pathways, we examined translocation formation in Xrcc4/ligase IV-deficient cells. We find that Xrcc4/ligase IV is not required for, but rather suppresses, translocations. Translocation breakpoint junctions have similar characteristics in wild-type and Xrcc4/ligase IV-deficient cells, including an unchanged bias toward microhomology, unlike what is observed for intrachromosomal DSB repair. Complex insertions in some junctions demonstrate that joining can be iterative, encompassing successive processing steps prior to joining. Our results imply that alt-NHEJ is the primary mediator of translocation formation in mammalian cells.

Nonhomologous end-joining (NHEJ) is the primary DNA repair pathway thought to underlie chromosomal translocations and other genomic rearrangements in somatic cells. The canonical NHEJ pathway, including DNA ligase IV (Lig4), suppresses genomic instability and chromosomal translocations, leading to the notion that a poorly defined, alternative NHEJ (alt-NHEJ) pathway generates these rearrangements. Here, we investigate the DNA ligase requirement of chromosomal translocation formation in mouse cells. Mammals have two other DNA ligases, Lig1 and Lig3, in addition to Lig4. As deletion of Lig3 results in cellular lethality due to its requirement in mitochondria, we used recently developed cell lines deficient in nuclear Lig3 but rescued for mitochondrial DNA ligase activity. Further, zinc finger endonucleases were used to generate DNA breaks at endogenous loci to induce translocations. Unlike with Lig4 deficiency, which causes an increase in translocation frequency, translocations are reduced in frequency in the absence of Lig3. Residual translocations in Lig3-deficient cells do not show a bias toward use of pre-existing microhomology at the breakpoint junctions, unlike either wild-type or Lig4-deficient cells, consistent with the notion that alt-NHEJ is impaired with Lig3 loss. By contrast, Lig1 depletion in otherwise wild-type cells does not reduce translocations or affect microhomology use. However, translocations are further reduced in Lig3-deficient cells upon Lig1 knockdown, suggesting the existence of two alt-NHEJ pathways, one that is biased toward microhomology use and requires Lig3 and a back-up pathway which does not depend on microhomology and utilizes Lig1.

Mammalian cells have 3 ATP-dependent DNA ligases, which are required for DNA replication and repair1. Homologs of ligase I (Lig1) and ligase IV (Lig4) are ubiquitous in eukarya, whereas ligase III (Lig3), which has nuclear and mitochondrial forms, appears to be restricted to vertebrates. Lig3 is implicated in various DNA repair pathways with its partner protein XRCC11. Deletion of Lig3 results in early embryonic lethality in mice, as well as apparent cellular lethality2, which has precluded definitive characterization of Lig3 function. Here we used pre-emptive complementation to determine the viability requirement for Lig3 in mammalian cells and its requirement in DNA repair. Various forms of Lig3 were introduced stably into mouse embryonic stem (ES) cells containing a conditional allele of Lig3 that could be deleted with Cre recombinase. With this approach, we find that the mitochondrial, but not nuclear, Lig3 is required for cellular viability. Although the catalytic function of Lig3 is required, the zinc finger (ZnF) and BRCT domains of Lig3 are not. Remarkably, the viability requirement for Lig3 can be circumvented by targeting Lig1 to the mitochondria or expressing Chlorella virus DNA ligase, the minimal eukaryal nick-sealing enzyme3, or Escherichia coli LigA, an NAD+-dependent ligase1. Lig3 null cells are not sensitive to several DNA damaging agents that sensitize XRCC1-deficient cells4,5,6. Our results establish a role for Lig3 in mitochondria, but distinguish it from its interacting protein XRCC1.

The precise genetic manipulation of stem and precursor cells offers extraordinary potential for the analysis, prevention, and treatment of human malignancies. Chromosomal translocations are hallmarks of several tumor types where they are thought to have arisen in stem or precursor cells. Although approaches exist to study factors involved in translocation formation in mouse cells, approaches in human cells have been lacking, especially in relevant cell types. The technology of zinc finger nucleases (ZFNs) allows DNA double-strand breaks (DSBs) to be introduced into specified chromosomal loci. We harnessed this technology to induce chromosomal translocations in human cells by generating concurrent DSBs at 2 endogenous loci, the PPP1R12C/p84 gene on chromosome 19 and the IL2R␥ gene on the X chromosome. Translocation breakpoint junctions for t(19;X) were detected with nested quantitative PCR in a high throughput 96-well format using denaturation curves and DNA sequencing in a variety of human cell types, including embryonic stem (hES) cells and hES cell-derived mesenchymal precursor cells. Although readily detected, translocations were less frequent than repair of a single DSB by gene targeting or nonhomologous end-joining, neither of which leads to gross chromosomal rearrangements. While previous studies have relied on laborious genetic modification of cells and extensive growth in culture, the approach described in this report is readily applicable to primary human cells, including mutipotent and pluripotent cells, to uncover both the underlying mechanisms and phenotypic consequences of targeted translocations and other genomic rearrangements.double-strand break repair (DSB repair) ͉ zinc finger nucleases ͉ mesenchymal cells ͉ gene targeting ͉ nonhomologous end-joining (NHEJ) R ecurrent chromosomal translocations are associated with many cancers where they are considered to be the initiating event for tumorigenic transformation. As many as half of hematological malignancies have a specific translocation signature, as do a number of tumors of mesenchymal origin, including Ewing's sarcoma, rhabdomyosarcoma, and synovial sarcoma (1, 2). Recurrent oncogenic chromosomal rearrangements have also recently been identified in some carcinomas, including tumors of the prostate (3) and small cell lung cancer (4), raising the possibility that they have a more widespread contribution to the etiology of solid tumors of epithelial origin than was previously recognized (5).Given the prevalence of chromosomal translocations in human malignancy, understanding how translocations are formed in human cells and the factors involved in their formation could lead to measures to prevent their occurrence. The initiating lesions in most cases are likely to be contemporaneous DNA double-strand breaks (DSBs) on heterologous chromosomes that are misjoined (2, 6). Sequencing of numerous breakpoint junctions from human translocations indicates that a nonhomologous end-joining (NHEJ) pathway of DSB repair gives rise to the misjoining events, sinc...

The ribosome is one of life’s most ancient molecular machines that has historically been viewed as a backstage participant in gene regulation, translating the genetic code across all kingdoms of life in a rote-like fashion. However, recent studies suggest that intrinsic components of the ribosome can be regulated and diversified as a means to intricately control the expression of the cellular proteome. In this review, we discuss advances in the characterization of ribosome post-translational modifications (PTMs) from past to present. We specifically focus on emerging examples of ribosome phosphorylation and ubiquitylation, which are beginning to showcase that PTMs of the ribosome are versatile, may have functional consequences for translational control, and are intimately linked to human disease. We further highlight the key questions that remain to be addressed to gain a more complete picture of the array of ribosome PTMs and the upstream enzymes that control them, which may endow ribosomes with greater regulatory potential in gene regulation and control of cellular homeostasis.

Available data and models for the health-economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant an update on the challenges associated with their economic evaluation. The perspectives of the co-authors were complemented with a targeted review of literature discussing methodological issues and data gaps in AD health-economic modelling. The methods and data available to translate treatment efficacy in early disease into long-term outcomes of relevance to policy makers and payers are limited. Current long-term large-scale data accurately representing the continuous, multifaceted, and heterogeneous disease process are missing. The potential effect of disease-modifying treatment on key long-term outcomes such as institutionalization and death is uncertain but may have great effect on cost-effectiveness. Future research should give priority to collaborative efforts to access better data on the natural progression of AD and its association with key long-term outcomes.

Lig1 and Lig4 are found throughout eukaryotes. Lig1 is considered to be the critical ligase during replication of the nuclear genome, while Lig4 is critical for the repair of double-strand breaks (DSBs) by nonhomologous end joining (NHEJ). Lig3 has been implicated both in nuclear DNA repair and in mitochondrial genome maintenance.3,4 Although Lig3 has a more restricted phylogenetic distribution in eukaryotes than the other two ligases, it is found more broadly in eukaryotic groups than originally thought, as will be discussed below. Lig3 is Essential for Cellular Viability due to its Role in MitochondriaRecent work using both cell complementation and tissue-specific deletion in the animal has shed light on the role of Lig3.5-7 Lig3-null mouse embryos die at ~8.5 dpc and previous attempts to generate Lig3-null cells were unsuccessful, 8 suggesting that Lig3 is required for cell survival. To directly determine whether Lig3 is an essential gene in cells, we developed a pre-emptive complementation strategy in mouse embryonic stem (ES) cells (Fig. 1)